Healthspan Capital

Healthspan Capital invests in early-stage companies developing therapies, diagnostics, and digital health tools that target the biology of aging. Its mandate covers drug discovery platforms aimed at cellular senescence and epigenetic reprogramming, as well as consumer and clinical tools for measuring biological age. The firm focuses on seed and start-up rounds where foundational aging science is being translated for the first time.

The firm dedicates its entire mandate to the biology of aging rather than treating specific diseases in isolation. While a general biotech fund might invest in an oncology or neurology asset, Healthspan Capital evaluates whether a company's platform addresses the underlying aging processes that cause multiple age-related diseases simultaneously. This thesis purity gives it a different sourcing and diligence lens.

Healthspan Capital has not publicly disclosed the names of its managing partners or investment committee members. The firm's decision-making structure and team composition are not available from public record as of the latest review. Limited partners or potential co-investors would need to engage directly to understand the investment team's scientific and operational backgrounds.

The firm operates as a venture capital manager making direct equity investments into early-stage companies, primarily in seed and start-up rounds. There is no public record indicating it participates as a fund-of-funds or commits capital to third-party managers. Its model centers on primary, direct positions in the longevity sector.

Healthspan Capital deploys at the earliest stages of company formation — seed and start-up — where geroscience discoveries exit academic labs and require initial venture backing. This includes pre-revenue biotech platforms, proof-of-concept diagnostics, and digital health tools that measure hallmarks of aging. The firm does not publicly list later-stage growth equity or public-market mandates.